Search

Author/Creator Johnson, Reed

2. A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. (April 2022)

Authors:
Cohen, Jeffrey A; Cameron, Michelle H; Goldman, Myla D; Goodman, Andrew D; Miller, Aaron E; Rollins, Anne; Llorens, Lily; Patni, Rajiv; Elfont, Robert; Johnson, Reed
Journal:
Multiple sclerosis
Issue:
Volume 28:Number 5(2022)
Page Start:
817
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Grassy–herbaceous land moderates regional climate effects on honey bee colonies in the Northcentral US. (1st June 2022)

Authors:
Quinlan, Gabriela M; Sponsler, Douglas; Gaines-Day, Hannah R; McMinn-Sauder, Harper B G; Otto, Clint R V; Smart, Autumn H; Colin, Théotime; Gratton, Claudio; Isaacs, Rufus; Johnson, Reed; Milbrath, Meghan O; Grozinger, Christina M
Journal:
Environmental research letters
Issue:
Volume 17:Number 6(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102. Issue 2 (23rd February 2018)

Authors:
Isaacson, Stuart H.; Fahn, Stanley; Pahwa, Rajesh; Tanner, Caroline M.; Espay, Alberto J.; Trenkwalder, Claudia; Adler, Charles H.; Patni, Rajiv; Johnson, Reed
Journal:
Movement disorders clinical practice
Issue:
Volume 5:Issue 2(2018)
Page Start:
183
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗